Boston Scientific (BSX) Accumulated Expenses (2009 - 2026)

Boston Scientific has disclosed Accumulated Expenses across 18 years of filings, most recently posting $2.5 billion for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $2.5 billion, up 6.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.5 billion (up 6.8% YoY), and the FY2025 annual result was $3.2 billion, up 15.43% from the prior year.
• Accumulated Expenses came in at $2.5 billion for Q1 2026 at Boston Scientific, down from $3.2 billion in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $3.2 billion in Q4 2025 to a low of $1.9 billion in Q1 2023.
• The 5-year median for Accumulated Expenses is $2.3 billion (2024), against an average of $2.4 billion.
• Across the five-year window, Accumulated Expenses declined 18.36% in 2022 and gained 22.5% in 2023, its largest moves.
• Boston Scientific's Accumulated Expenses stood at $2.2 billion in 2022, then climbed by 22.5% to $2.6 billion in 2023, then climbed by 4.8% to $2.8 billion in 2024, then climbed by 15.43% to $3.2 billion in 2025, then slipped by 21.46% to $2.5 billion in 2026.
• The last three Accumulated Expenses figures came in at $2.5 billion (Q1 2026), $3.2 billion (Q4 2025), and $3.0 billion (Q3 2025), per Business Quant data.